Infliximab: 12 Years of Experience
Author Information
Author(s): Smolen Josef S, Emery Paul
Primary Institution: Medical University of Vienna
Hypothesis
Can infliximab effectively treat rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis?
Conclusion
Infliximab has been shown to effectively treat the signs and symptoms of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis, providing rapid and prolonged suppression of inflammation.
Supporting Evidence
- Infliximab effectively treats the signs and symptoms of rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis.
- Patients receiving infliximab showed significant improvements in physical function and quality of life.
- Infliximab has a well-established safety profile based on 12 years of clinical use.
Takeaway
Infliximab is a medicine that helps people with certain types of arthritis feel better by reducing swelling and pain in their joints.
Methodology
The study involved randomized controlled trials and observational studies assessing the efficacy of infliximab in patients with rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis.
Potential Biases
Potential bias may arise from the sponsorship of the publication by Merck & Company.
Limitations
The study may not fully account for long-term effects and the variability in patient responses to infliximab.
Participant Demographics
Patients included were diagnosed with rheumatoid arthritis, ankylosing spondylitis, or psoriatic arthritis.
Statistical Information
P-Value
p<0.001
Statistical Significance
p<0.001
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website